Literature DB >> 19487292

Promyelocytic leukemia protein is required for gain of function by mutant p53.

Sue Haupt1, Silvia di Agostino, Inbal Mizrahi, Osnat Alsheich-Bartok, Mathijs Voorhoeve, Alex Damalas, Giovanni Blandino, Ygal Haupt.   

Abstract

Mutations in the p53 tumor suppressor are the most common genetic events in human cancer. These mutations not only result in a loss of wild-type p53 activity, but can also lead to a gain of new oncogenic properties. Understanding how these gained functions are regulated is in its infancy. In this study, we show that the promyelocytic leukemia (PML) protein is an important regulator of mutant p53. We show that PML interacts with mutant p53. Importantly, PML enhances the transcriptional activity of mutant p53. Unexpectedly, PML is required for the proliferation and colony formation of cancer cells bearing mutant p53. Down-regulation of PML expression inhibits the growth of mutant p53-expressing cancer cells, predominantly by promoting cell cycle arrest. Our results suggest that the tumor suppression function of PML depends on the status of p53. In the context of mutant p53, PML enhances its cancer-promoting activities.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19487292     DOI: 10.1158/0008-5472.CAN-08-4010

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  36 in total

Review 1.  Role of the nucleus in apoptosis: signaling and execution.

Authors:  Evgeniia A Prokhorova; Alexey V Zamaraev; Gelina S Kopeina; Boris Zhivotovsky; Inna N Lavrik
Journal:  Cell Mol Life Sci       Date:  2015-09-07       Impact factor: 9.261

2.  Loss of PML cooperates with mutant p53 to drive more aggressive cancers in a gender-dependent manner.

Authors:  Sue Haupt; Catherine Mitchell; Vincent Corneille; Jake Shortt; Stephen Fox; Pier Paolo Pandolfi; Mireia Castillo-Martin; Dennis M Bonal; Carlos Cordon-Cardo; Guillermina Lozano; Ygal Haupt
Journal:  Cell Cycle       Date:  2013-05-08       Impact factor: 4.534

3.  Promyelocytic leukemia nuclear bodies support a late step in DNA double-strand break repair by homologous recombination.

Authors:  Percy Luk Yeung; Natalia G Denissova; Cara Nasello; Zhanna Hakhverdyan; J Don Chen; Mark A Brenneman
Journal:  J Cell Biochem       Date:  2012-05       Impact factor: 4.429

Review 4.  TRIMming p53's anticancer activity.

Authors:  S Elabd; G Meroni; C Blattner
Journal:  Oncogene       Date:  2016-02-22       Impact factor: 9.867

Review 5.  Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others.

Authors:  Kanaga Sabapathy; David P Lane
Journal:  Nat Rev Clin Oncol       Date:  2017-09-26       Impact factor: 66.675

6.  Pontin, a new mutant p53-binding protein, promotes gain-of-function of mutant p53.

Authors:  Y Zhao; C Zhang; X Yue; X Li; J Liu; H Yu; V A Belyi; Q Yang; Z Feng; W Hu
Journal:  Cell Death Differ       Date:  2015-04-10       Impact factor: 15.828

7.  The gain of function of p53 cancer mutant in promoting mammary tumorigenesis.

Authors:  X Lu; D P Liu; Y Xu
Journal:  Oncogene       Date:  2012-07-23       Impact factor: 9.867

Review 8.  Mutant TP53 posttranslational modifications: challenges and opportunities.

Authors:  Thuy-Ai Nguyen; Daniel Menendez; Michael A Resnick; Carl W Anderson
Journal:  Hum Mutat       Date:  2014-02-11       Impact factor: 4.878

9.  Ectopic expression of p33ING1b suppresses proliferation and induces apoptosis in colonic adenocarcinoma cells.

Authors:  A I Jia; Yifei Lv; Xueyan Guo; L I Ren; Jie Qin
Journal:  Oncol Lett       Date:  2015-06-17       Impact factor: 2.967

Review 10.  When mutants gain new powers: news from the mutant p53 field.

Authors:  Ran Brosh; Varda Rotter
Journal:  Nat Rev Cancer       Date:  2009-08-20       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.